Introduction
Despite progress in the treatment of chronic lymphocytic leukemia (CLL) conventional treatment regimens are not curative. Allogeneic hematopoietic cell transplantation (HCT) represents a potentially curative treatment modality for several hematologic malignancies, but the use of myeloablative conditioning regimens has been associated with high treatment related mortality in CLL patients. [1] [2] [3] Because of the reduced toxicity of conditioning regimens, which are nonmyeloablative (NMA) or have reduced intensity, there has been a renewed interest in the use of allogeneic HCT in the treatment of CLL. [4] [5] [6] [7] [8] [9] [10] The curative principle in allogeneic HCT with NMA conditioning is the Graft-versus-Leukemia (GVL) effect, and data from several studies have indicated that a GVL effect is elicited after allogeneic HCT in CLL patients. 5, 7, 9, [11] [12] [13] [14] [15] Several lines of evidence strongly suggest that donor T cells are involved in the antitumor effects following HCT. 16 In human leukocyte antigen (HLA) identical HCT, T-cell responses to minor histocompatibility antigens (mHAgs) -at least in part -are responsible for the GVL effect but also cause Graft-versus-Host disease (GVHD). [17] [18] [19] [20] Separation of GVL and GVHD would potentially set the stage for GVL in the absence of GVHD, in turn implying that response rates would increase in the absence of adverse treatment induced side effects. This would allow treatment of a larger fraction of patients. 21 Clonotype analyses of T cells in cancer, for example, of tumor infiltrating lymphocytes in solid tumors have been used in many studies as an indication of an ongoing T-cell response directed against the tumor. 22 Moreover, available methods for detection of clonally expanded T cells offer the means to present a 'molecular fingerprint' of specific T cells, implying that such cells can be monitored in space and time. To this end, a number of studies have been performed with a focus on T-cell clonality in peripheral blood mononuclear cells (PBMC) following HCT. Important data with regards to immune reconstitution have been achieved aided by such analyses of T-cell clonality, for example, by single strand conformational polymorphism (SSCP), 23 or more recently CDR3 size spectratyping. 24 Obviously, analyses of that character may provide important new insight into the fate and function of T cells in HCT. 25 In the present study, we used the T-cell receptor (TCR) clonotype mapping methodology in longitudinal analyses of clonality of CD8 þ T cells following HCT. Moreover, we took advantage of the tracking ability of TCR clonotype mapping and combined these analyses with analyses of functionality, with the aim of investigating the presence and recurrence of such cells in relation to the clinical response, that is, disease progression, remission, and GVHD.
Materials and methods

Treatment
Two patients (unique patient number (UPN) 682 and UPN 766), diagnosed with CLL received peripheral blood stem cells from their HLA-identical siblings after NMA conditioning with fludarabine 90 mg/m 2 and 2 Gy of total body irradiation, as previously described. 26 Post-transplant immunosuppression consisted of oral cyclosporin 12.5 mg/kg/day and mycophenolate mofetil 30 mg/kg/day. Acute and chronic GVHD were graded according to standard criteria. 27 The study was approved by the local ethics committee, and patients provided informed consent to participate. grafts were analyzed in the present study as donor samples. For patient UPN 682 cells for donor lymphocyte infusion (DLI) were harvested 14 days prior to harvest of the graft. Post-transplant, heparinized peripheral blood samples were obtained from the patients, and PBMC were separated by gradient centrifugation (Lymphoprep, Axia Shield PoC, Oslo, Norway), and cryopreserved.
Chimerism and HA-1/2 parity analyses
The levels of donor CD4 þ and CD8 þ T-cell chimerism in peripheral blood were determined sequentially post-transplant by use of fluorescence-based PCR of short tandem repeats. 29, 30 Complete donor chimerism was defined as 499% donor cells.
As HA-1 and HA-2 mismatches are highly relevant in relation to monitoring of anticancer reactivity in the recipients following HCT the donors and recipients were typed by PCR amplification and direct sequencing (data not shown). Both patient/donor pairs were characterized for HA-1, and HA-2 parity.
Minimal residual disease (MRD)
Clonal rearrangements of the genes coding for the immunoglobulin heavy chain were detected pre-transplant. Quantitative PCR with clone specific IgH primers was used to detect MRD after the transplant. 31 Molecular remission was defined as o1 malignant cell in 100 000 normal cells.
Purification of CD8
þ T cells 
TCR clonotype mapping by denaturing gradient gel electrophoresis (DGGE)
RNA was extracted using the NucleoSpin RNA II (MachereyNagel, Germany). cDNA synthesis and quantitation of cDNA in each sample was carried out as previously described. 32 For FACS sorted cells, RNA was prepared as described. 33 In short, cells were lysed by freeze/thawing in a 5-10 ml volume of first strand buffer, and cDNA synthesis carried out directly in the presence of RNAse inhibitor.
For TCR clonotype mapping, cDNA was amplified using a primer panel covering the 24 BV region families of the TCR. Resulting PCR products are suited for denaturing gradient gel electrophoresis (DGGE). 33, 34 Amplifications were carried out in a total volume of 45 ml containing 1 Â PCR buffer (50 mM KCl, 20 mM Tris pH 8.4, 2.0 mM MgCl 2 , 0.2 mM cresol red, 12% sucrose, 0.005% (wt/v) BSA (Boehringer-Mannheim, Mannheim, Germany)), 2.5 pmol of each primer, 40 mM dNTPs (Pharmacia LKB, Uppsala, Sweden) and 1.25 U of AmpliTaq polymerase (Perkin Elmer Cetus Corporation, Emeryville, CA, USA). Parameters and conditions used for amplification were 941C for 30 s, 601C for 60 s, and 721C for 60 s, as described. 32, 33 For DGGE 10 ml aliquots were loaded onto a denaturing gradient gel containing 6% polyacrylamide and a gradient of urea and formamide ranging from 20 to 80%. Gels were run at 160 V for 4.5 h in 1 Â TAE buffer kept at a constant temperature of 561C. After electrophoresis, the gel was stained with SYBR s Green I (Molecular Probes, Oregon, USA) and visualized using the FLA-3000 fluorescence detection system (FUJI film, Science Imaging Scandinavia, Sweden). Detection of bands in the gels was carried out taking advantage of the TotalLabSoftware (Nonlinear Dynamics, UK).
Comparative TCR clonotype mapping
For comparative analyses of TCR clonotype transcripts, for example, for comparison of clonotypes at specific time points following HCT, 10 ml aliquots were loaded onto a denaturing gradient gel in adjacent lanes. Gels were stained as described above.
Purification of CLL cells
In UPN 766, CLL cells were isolated by magnetic beads (MACS, Miltenyi Biotech, Germany) from pre-transplant PBMC samples containing 30% tumor cells (data not shown). Data from FACS analyses of pre-transplant PBMC demonstrated that all CD19 þ cells were double positive CD5 þ CD19 þ . As a consequence, CD19 beads were used for positive isolation af CLL cells. Briefly, samples were suspended in PBS supplemented with 2% FCS, and incubated with anti-CD19 microbeads. After incubation for 20 min in the dark, cells were washed and CD19
þ CLL cells were isolated according to manufacturer's suggestions, and used for immediate co-culture.
Coculture of CLL cells and CLL depleted PBMC with post-transplant CD8
þ T cells
Post-transplant CD8 þ T cells were purified from samples obtained on day þ 259 in UPN 682, and on day þ 153 in UPN 766, and cultured overnight 1 day prior to stimulation to avoid background CD107a staining. Next day CLL cells and CLL depleted PBMC, respectively, were mixed with purified CD8
þ T cells at a 1:1 ratio and incubated at 371C for 4 h. In UPN 766 sufficent cell numbers were available to establish separate cultures of CD8 þ T cells and CLL cells, and CD8 þ T cells and normal nonmalignant patient cells. In UPN 682 cell numbers were too low for separate cultures, thus, CD8 þ T cells were stimulated with normal CD8 depleted PBMC and CLL cells in a single culture. However, the CLL cell constituent was above 70% (data not shown).
Flow cytometry and sorting of CD107a positive T cells
PE-coupled CD107a mAb (B&D) was added and the cell mixture was cultured at 371C for 4 h. Brefeldin A (Sigma) 1 mg/ml was added after 1 h, cells were washed and stained with anti-CD8 þ mAb (APC-Cy7). Positively stained T cells were sorted by FACS, snap frozen or immediately processed for TCR clonotype mapping. þ cells/kg) on day þ 116. At 5 months posttransplant enlarged lymph nodes appeared on the neck, in the axillary regions, and in the mediastinum. A lymph node on the neck was removed on day þ 172 in an attempt to distinguish between disease progression and inflammation caused by a GVL effect. CLL cells and T cells dominated the lymph node. Complete donor T cell chimerism occurred on day þ 231. The enlarged lymph nodes slowly regressed and disappeared by day þ 259 at this time the patient also developed extensive chronic GVHD. Molecular remission in blood and bone marrow was obtained on day þ 259 and is maintained at the latest follow-up at 4.2 years post-transplant. The patient is still receiving immunosuppression because of extensive chronic GVHD with scleroderma.
Results
Patients
UPN 766 was 52 years old, when diagnosed with CLL. He received six treatment regimens including rituximab before the transplantation. At the time of transplant 5 years after the diagnosis he was in partial remission. He developed acute GVHD grade II on day þ 31, and was treated with prednisolone 2 mg/kg/day (Figure 1b) . Immunosuppression was tapered from day þ 96 because of persistent CLL. On day þ 138 the patient was admitted and treated for pneumonia. At the same time increasing liver enzymes and CD3 þ T-cell counts up to 29.6 Â 10 9 /l were observed. He developed extensive chronic GVHD on day þ 146 and was treated with various immunosuppressants including rituximab 375 mg/m 2 on day þ 174 and þ 186. Complete donor T cell chimerism was obtained on day þ 154. Molecular remission in the bone marrow was obtained on day þ 264 and is maintained at the latest follow-up þ 2.7 years post-transplant. The patient is still on immunosuppression because of extensive chronic GVHD.
Both patients and donors had positive antibody (IgG) titres against cytomegalovirus (CMV) before the transplantation.
TCR clonotype mapping
Isolated CD8
þ T-cell populations were analyzed for the presence of T-cell clonotypes by RT-PCR/DGGE based TCR clonotype mapping. Data from these analyses revealed the presence of multiple clonotypic TCR transcripts covering the majority of the BV families 1-24 (data not shown). TCR clonotype analyses of CD8 þ T cells isolated following HCT were conducted at specific time points after HCT. In UPN 682 last included analyses represent day þ 748; in UPN 766 last included analyses represent day þ 369. Clonally
To investigate whether clonotypes identified in blood samples at individual time points could recurrently be detected in one or several other blood samples from the same patient, all clonotypes in the individual BV families were compared throughout the follow-up period as indicated above. These data demonstrated that indeed stable T-cell clonotypes were detectable. In particular, such stable clonotypes could be detected in blood samples from approximately day 140-150 and throughout the monitoring period, in both patients (Figure 2a and b) . There was a tendency to a high degree of clonotype dynamics in the early phase following HCT, as also clearly indicated by Figure 2a and b. This tendency was apparent in both patients upon calculation of the dynamics considering all 24 TCRBV regions, and is shown schematically in Figure 2c .
TCR clonotype mapping in relation to donor lymphocyte infusion (DLI)
In UPN 682 well-defined clonotypes were observed on day þ 53 in BV regions 18 and 21 ( Figure 3a) . As the malignant disease progressed, these clonotypes slowly disappeared and reappeared after DLI, that is, correlating with disease regression. Notably, DLI also coincided with appearance of clonotypes not previously detected. These clonotypes (eg, TCRBV11, 15, and 24) remained stable throughout the monitoring period (Figure 3b , and data not shown).
An enlarged lymph node was resected from the neck of UPN 682 at day þ 172. TCR clonotype mapping and comparison to clonotypes previously detected both before and after DLI, demonstrated that specific recurrent clonotypes were present in the tumor infiltrated lymph node (data not shown). T cell clonotype dynamics by comparative TCR clonotype mapping. TCR clonotype mapping was used for a longitudinal comparative analysis of CD8 þ T-cell clonotypes detected in PBMC following HCT. Examples are given for UPN 682, representing the TCR clonotypes TCRBV20, and 24 (a), and UPN 766, representing the TCR clonotypes TCRBV11 and 17 (b). Black arrows indicate stable clonotypes. Schematic presentation of the dynamics of CD8 þ T-cell clonality over time. Dynamics was scored as þ 1 when a clonotype disappeared/appeared from one time point to the next, whereas a 'no change', that is, the presence of a stable clonotype from one time point to the next scored 0 (c).
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Flow cytometry clonotypes. Importantly, the TCRBV21 clonotype was identified as a stable clonotype both before and after DLI. Moreover, the TCRBV11, and 15 clonotypes were detected in the lymph node resected at day þ 172 (data not shown). Although the CD8 þ T cells in UPN 682 were stimulated with unpurified CD8 depleted PBMC, this strongly suggests the CLL specificity of these T cells. In UPN 766, T-cell stimulation was conducted with (1) purified CLL cells from a pre-transplant PBMC sample, and (2) 
Discussion
The anti-tumor effect of NMA-HCT is solely related to cells and molecules in the graft. It is well recognized that donor T cells are crucial for the therapeutic efficacy of the treatment, but the targets recognized and the specificity and phenotypic characteristics of therapeutic T cells remain largely unknown. In the present study, we have conducted a longitudinal analysis of clonally expanded T cells in CLL patients receiving NMA-HCT. One of the aims of the study was to elucidate the dynamics of CD8 þ T-cell clonotypes in relation to clinical data of the patients.
The longitudinal analyses of T-cell clonotypes in both patients showed a clear tendency towards a decrease in heterogeneity with time (Figure 2c ). Several studies have described longitudinal T-cell clonality in HCT, however, in most cases in a therapeutic setting significantly different from the present, for example, by manipulations of the graft or infused lymphocytes, that is, by depletion of T cells or T-cell subsets. 24, 35 Masuko et al, 23 used SSCP, to study CD8 þ T-cell clonality after conventional allogeneic HCT in patients diagnosed with various hematological malignancies. As in the present study, the data demonstrated an early expansion of dynamic T-cell clonotypes, and the subsequent appearance of stable CD8 þ clonotypes. Clearly, these data support our findings, and indicate an initial acute phase of the response. 23 Potentially, this early -and clonotypically highly dynamic response -could be related to donor cell recognition of numerous antigens on recipient cells; malignant cells as well as a variety of hematopoietic normal cells. At later phases, the numbers of normal cells -including Figure 3 Comparative TCR clonotype mapping of CD8 þ T cells in UPN 682, before and after donor lymphocyte infusion (DLI). TCR clonotype mapping was used for a longitudinal comparative analysis of CD8 þ T-cell clonotypes detected in PBMC following HCT; before and after DLI. The donor sample was harvested two weeks apart from the sample used for DLI (not analyzed for clonality). The TCR clonotypes TCRBV18 (upper gel), and TCRBV21 (lower gel), disappeared at the time of disease progression and DLI, but reappeared after DLI at day þ 154 (a). TCR clonotypes TCRBV11 (upper gel), and TCRBV24 (lower gel) -not previously detected in vivo -emerged subsequent to DLI, and were detectable throughout the monitoring period (b). Red arrowhead indicates disease progression, black arrowhead indicates DLI, and black arrows indicate stable clonotypes. Identity of selected transcripts was verified by sequence analysis (data not shown).
Clonally expanded cytotoxic T cells in CLL patients receiving HCT T Kollgaard et al professional APC -of patient origin decrease, in turn leading to a more homogeneous response. 36 In the study of Masuko et al, 23 monitoring of patients at several time points after HCT revealed that the numbers of recurrent T-cell clonotypes diminished with time. In the present study, we did not detect such a decrease in stable T-cell clonotypes; even at 2 years after HCT stable CD8 þ T-cell expansions were readily detectable. However, in the present study both patients were characterized by extensive chronic GVHD, whereas in the patients studied by Masuko et al, this was not the case. Thus, the long-term persistency of the CD8 þ clonality revealed in the present study could in part be related to GVHD.
Clearly, the persistence of specific T-cell clonotypes over extended periods of time suggests that these T cells are stimulated by antigen. In a longitudinal study of allogeneic HCT for myeloid leukemia, clonality was studied by CDR3 spectratyping and sequencing.
37 Surprisingly, it was found that pre-existing T-cell clonotypes expanded in the donor persisted for extended time in the recipient. The authors suggested that these cells are involved with responses against CMV. In our study, we detected a T-cell clonotype expanded in donor PBMC, subsequently detectable in the patient throughout the monitoring period (data not shown). Clearly, antigens representing natural targets in donor as well as patient are likely to be the targets for these T cells, for example, CMV or other viruses.
In UPN 682, disease progression was treated by DLI at day þ 116, upon which the tumor went into slow regression and the patient experienced complete molecular remission approximately 5 months later, now exceeding 49 months. Strikingly, prior to disease progression (day þ 66) previously detected stable T-cell clonotypes became undetectable in PBMC, but reappeared at day þ 154, and remained detectable throughout the monitoring period (Figure 3 ). In addition, new clonally expanded T cells emerged at day þ 154, and remained present throughout the monitoring period. Importantly, the appearance of these T-cell clonotypes coincided with induction of complete molecular remission. Also, several of these clonotypes were detected in a lymph node resected from the patient at day þ 172 (data not shown). Together, these data suggest that the appearance of CD8 þ clonotypes is directed by antigens expressed on CLL cells.
Characterization of the clinically relevant target structures recognized by donor T cells following HCT is of obvious interest, and several lines of evidence have demonstrated that mHAgs represent targets for recognition of T cells following HCT. 20, 38, 39 The mHAgs HA-1 and HA-2 have been suggested to represent immune dominant targets at mismatch between donor and patient. Genetic analyses, however, demonstrated these mHAgs to be irrelevant in the present study, and there is consensus that still unrevealed targets may be of equal importance. 40 Stimulation of ex vivo purified recipient CD8 þ T cells with CLL cells or mixtures of patient cells were shown to induce surface expression of the CD107a molecule by the T cells, strongly suggesting that some of the peripheral CD8 þ T cells exert cytotoxic activity against CLL cells. TCR clonotype mapping of CD107a positive cells demonstrated the oligoclonal nature of the population (data not shown), and set the stage for comparative clonotype analyses to reveal whether these cells were clonally expanded in vivo. As shown in Figure 4 , several CD107a positive T cells were indeed detectable as stable T-cell clonotypes in vivo following HCT. For UPN 682, the TCRBV21 clonotype -present in the CD107a population -was detectable as a stable TCR clonotype in PBMC as early as day þ 53 following HCT. Upon disease progression this clonotype disappeared from the blood stream, but was recurrently detectable after DLI. Thus, at day þ 154 TCRBV21 reappeared -and TCRBV11 and 15 emerged for the first time (Figure 4) . Moreover, TCRBV11, and 15 were detectable in the resected lymph node. In this patient, CD107a expression was induced by stimulation with nonsorted cells, that is, both CLL cells and remaining PBMC. Therefore, it cannot be excluded that these clonotypes are specific for normal recipient cells, and not tumor cells. Disease remission coincided with appearance/reappearance of clonotypes suggesting that these expanded T cells are tumor specific and play an active role in disease remission.
Several lines of evidence have demonstrated that GVHD and GVL are intimately associated, 41 which could point to a scenario in which identical targets are recognized on normal cells and cancer cells. However, another possibility could be that the onset of GVHD initiates an immunological alertness in turn leading to GVL. This hypothesis is in compliance with the demonstration that GVL and GVHD may in fact be separated, 42 and also more appropriately abide the fact that some hematological malignancies are far more susceptible to GVL than others. In this respect, there are major differences in the clinical efficacy associated with HCT -depending to a large extent on disease entity. 43 Summing up, we have conducted a longitudinal analysis of CD8 þ T-cell clonotypes in CLL patients following HCT. Our results based on clonotype analyses of sorted CD8
þ T cells, demonstrate that an early highly dynamic phase is replaced by appearance of stable T-cell clonotypes several months after HCT. These data suggest that clonality is directed by antigen, a notion supported by the recurrence of T-cell clonotypes after DLI. Moreover, surface expression of CD107a by T cells upon co-culture with patient cells strongly suggests that donor T cells participate in ongoing GVL and GVHD. Importantly, our results support data from studies in animal models, 42 suggesting that GVL and GVHD are the results of distinct responses, possibly involving separate targets. Future identification and characterization of the antigens involved in GVL and GVHD, may set the stage for separation of GVHD and GVL, which in turn may ease the way to further improvements of the effect of GVL, for example, by vaccination or adoptive transfer of specific T cells.
